In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GNI Group Ltd.

www.gnipharma.com

Latest From GNI Group Ltd.

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

China’s HEC Plans Novel IPF Study To Make Splash In US

Tommy Lin, head of Business Development and Global Licensing for HEC Pharma, talks to Scrip’s Brian Yang on how the Chinese domestic drug company is looking to develop its anti-fibrosis drug in the US.

Commercial China

Brazil to secure good hep C prices, but what about other expensive drugs?

The cost of hepatitis C drugs has prompted strong reactions across the world from India to Spain, but not so in Brazil where the government looks close to agreeing a favorable price with the manufacturers. Unfazed by its faltering economy and increasingly unsustainable healthcare system, Brazil's health ministry says it is set to offer free access to Bristol-Myers Squibb's Daklinza (daclatasvir), Gilead's Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir).

Spain

Japan Bioventures SymBio, GNI Spread U.S. Wings

Trying to address some of the expansion challenges faced by their peers, two Japanese bioventures have taken steps to boost their presence and profile in the U.S.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Gene Networks International Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • GNI Group Ltd.
  • Senior Management
  • Ying Luo, PhD, CEO
    Ken Suzuki, CFO
  • Contact Info
  • GNI Group Ltd.
    Phone: (81) 03-3580-0751
    Kasumigaseki IHF Bldg. 3-5-1
    Tokyo, 100-0013
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register